BACKGROUND: Vitreoretinal disorders, including proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR) and exudative age-related macular degeneration (AMD), are a major cause of visual impairment worldwide and can lead to blindness when untreated. Loss of blood-retinal barrier (BRB) integrity associated with vitreoretinal fibrin deposition, inflammation, fibrosis and neovascularization contribute to the pathophysiological processes in these disorders. Retinal pigment epithelial (RPE) cells are well recognized to contribute to vitreoretinal inflammation/fibrosis and are likely to encounter contact with coagulation factor upon loss of BRB integrity. METHODS: An extensive study was performed in which we examined the effect of factor Xa and thrombin on the production of a broad panel of cytokines/chemokines and growth factors by RPE cells. For this purpose we used the ARPE-19 cell line as well as primary RPE cells, a glass slide based array that allows simultaneous detection of 120 cytokines/chemokines and growth factors, ELISA and real-time-quantitative PCR. The involved signaling cascade was examined using specific inhibitors for protease activated receptor (PAR)1, PAR2 and nuclear factor kappa-B (NF-κB). RESULTS: Factor Xa and thrombin regulated the production of cytokines and growth factors (including GM-CSF, IL-6, IL-8, MCP-3, PDGF-AA, PDGF-BB, TIMP-1 and TGF-α) that fit well in the pathobiology of vitreoretinal disease. Blocking studies revealed that the effects were mediated via PAR1 induced NF-κB activation. CONCLUSIONS: Our findings suggest that factor Xa and thrombin can drive vitreoretinal inflammation and fibrosis and should be considered as treatment targets in vitreoretinal disorders such as PVR, PDR and AMD.
BACKGROUND:Vitreoretinal disorders, including proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR) and exudative age-related macular degeneration (AMD), are a major cause of visual impairment worldwide and can lead to blindness when untreated. Loss of blood-retinal barrier (BRB) integrity associated with vitreoretinal fibrin deposition, inflammation, fibrosis and neovascularization contribute to the pathophysiological processes in these disorders. Retinal pigment epithelial (RPE) cells are well recognized to contribute to vitreoretinal inflammation/fibrosis and are likely to encounter contact with coagulation factor upon loss of BRB integrity. METHODS: An extensive study was performed in which we examined the effect of factor Xa and thrombin on the production of a broad panel of cytokines/chemokines and growth factors by RPE cells. For this purpose we used the ARPE-19 cell line as well as primary RPE cells, a glass slide based array that allows simultaneous detection of 120 cytokines/chemokines and growth factors, ELISA and real-time-quantitative PCR. The involved signaling cascade was examined using specific inhibitors for protease activated receptor (PAR)1, PAR2 and nuclear factor kappa-B (NF-κB). RESULTS:Factor Xa and thrombin regulated the production of cytokines and growth factors (including GM-CSF, IL-6, IL-8, MCP-3, PDGF-AA, PDGF-BB, TIMP-1 and TGF-α) that fit well in the pathobiology of vitreoretinal disease. Blocking studies revealed that the effects were mediated via PAR1 induced NF-κB activation. CONCLUSIONS: Our findings suggest that factor Xa and thrombin can drive vitreoretinal inflammation and fibrosis and should be considered as treatment targets in vitreoretinal disorders such as PVR, PDR and AMD.
Authors: L van Steensel; D Paridaens; M van Meurs; P M van Hagen; W A van den Bosch; R W A M Kuijpers; H A Drexhage; H Hooijkaas; W A Dik Journal: J Clin Endocrinol Metab Date: 2012-01-11 Impact factor: 5.958
Authors: Scott D Schoenberger; Stephen J Kim; Jinsong Sheng; Kasra A Rezaei; Maziar Lalezary; Edward Cherney Journal: Invest Ophthalmol Vis Sci Date: 2012-08-27 Impact factor: 4.799
Authors: Lukas J A G Ricker; Raed Al Dieri; Gerold J M Beckers; Elisabeth Pels; Albert T A Liem; Fred Hendrikse; Aize Kijlstra; H Coenraad Hemker; Ellen C La Heij Journal: Invest Ophthalmol Vis Sci Date: 2010-04-30 Impact factor: 4.799
Authors: L van Steensel; H Hooijkaas; D Paridaens; W A van den Bosch; R W A M Kuijpers; H A Drexhage; P M van Hagen; W A Dik Journal: J Clin Endocrinol Metab Date: 2012-03-21 Impact factor: 5.958
Authors: Chuong D Hoang; Xihong Zhang; Paul D Scott; Tenner J Guillaume; Michael A Maddaus; Douglas Yee; Robert A Kratzke Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: Francesco Morescalchi; Sarah Duse; Elena Gambicorti; Mario R Romano; Ciro Costagliola; Francesco Semeraro Journal: Mediators Inflamm Date: 2013-09-30 Impact factor: 4.711